Piramal Pharma Limited (NSE:PPLPHARMA)
India · Delayed Price · Currency is INR 211.50
-0.99 (-0.47%)
Sep 11, 2026, 3:29 PM IST
Piramal Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 280,940 | 181,305 | 297,962 | 170,528 | 81,683 | - | |
Market Cap Growth | 6.21% | -39.15% | 74.73% | 108.77% | - | - |
Enterprise Value | 324,505 | 222,374 | 341,742 | 209,922 | 130,128 | - |
Last Close Price | 211.35 | 136.54 | 224.60 | 128.72 | 66.76 | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | 326.96 | 956.95 | - | - |
Forward PE | 92.70 | 82.54 | 70.54 | 42.33 | 40.39 | - |
PS Ratio | 3.05 | 2.04 | 3.26 | 2.09 | 1.15 | - |
PB Ratio | 3.44 | 2.22 | 3.67 | 2.15 | 1.21 | - |
P/TBV Ratio | 6.99 | 4.51 | 7.38 | 4.71 | 3.51 | - |
P/FCF Ratio | 36.84 | 23.78 | 130.73 | 58.30 | - | - |
P/OCF Ratio | 17.00 | 10.97 | 33.39 | 16.98 | 16.88 | - |
PEG Ratio | - | 0.74 | 0.44 | 1.58 | 1.35 | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 3.53 | 2.51 | 3.73 | 2.57 | 1.84 | - |
EV/EBITDA Ratio | 32.36 | 26.62 | 24.92 | 18.43 | 22.58 | - |
EV/EBIT Ratio | 150.16 | 232.39 | 54.01 | 45.62 | - | - |
EV/FCF Ratio | 42.55 | 29.16 | 149.94 | 71.77 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.70 | 0.70 | 0.60 | 0.60 | 0.83 | 0.62 |
Debt / EBITDA Ratio | 6.05 | 6.47 | 3.44 | 4.00 | 9.21 | 3.63 |
Debt / FCF Ratio | - | 7.49 | 21.31 | 16.10 | - | - |
Net Debt / Equity Ratio | 0.53 | 0.53 | 0.55 | 0.53 | 0.74 | 0.57 |
Net Debt / EBITDA Ratio | 4.85 | 5.22 | 3.24 | 3.68 | 8.70 | 3.47 |
Net Debt / FCF Ratio | - | 5.71 | 19.52 | 14.34 | -10.43 | -31.27 |
Asset Turnover | - | 0.53 | 0.59 | 0.55 | 0.52 | 0.57 |
Inventory Turnover | - | 1.33 | 1.58 | 1.69 | 1.94 | 1.87 |
Quick Ratio | - | 0.76 | 0.75 | 0.61 | 0.64 | 0.69 |
Current Ratio | - | 1.51 | 1.54 | 1.25 | 1.26 | 1.34 |
Return on Equity (ROE) | - | -4.00% | 1.14% | 0.24% | -2.77% | 6.11% |
Return on Assets (ROA) | - | 0.36% | 2.55% | 1.93% | -0.20% | 2.96% |
Return on Invested Capital (ROIC) | 1.26% | 0.76% | 1.13% | 0.38% | -0.40% | 4.62% |
Return on Capital Employed (ROCE) | - | 0.70% | 5.30% | 4.20% | -0.40% | 5.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -1.12% | -1.80% | 0.31% | 0.10% | -2.28% | - |
FCF Yield | 2.71% | 4.21% | 0.77% | 1.71% | -5.89% | - |
Dividend Yield | 0.07% | - | 0.06% | 0.08% | - | - |
Payout Ratio | - | - | 15.88% | - | - | 13.30% |
Buyback Yield / Dilution | -0.01% | 0.40% | -3.67% | -7.85% | -0.95% | -87.83% |
Total Shareholder Return | 0.05% | 0.40% | -3.61% | -7.76% | -0.95% | -87.83% |